Hydroxyurea and Transfusion

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 30, 2018

Primary Completion Date

July 1, 2021

Study Completion Date

July 1, 2021

Conditions
Sickle Cell Disease
Interventions
DRUG

Hydroxyurea

Participants will be started on hydroxyurea 20 ± 2.5 mg/kg/day in addition to continuing simple chronic transfusion every 4 weeks ± 1 week. Hydroxyurea will be dose escalated to achieve a HAT target dose (HAT-TD). Hydroxyurea will be increased by 5 mg/kg/day after 8 weeks of a dose if HAT-TD is not achieved (maximum daily dose 2,000 mg). After HAT-TD has been achieved, minor dose increases may occur if subject grows a significant amount to maintain the same mg/kg dose.

Trial Locations (1)

20010

Children's National Health System, Washington D.C.

All Listed Sponsors
lead

Children's National Research Institute

OTHER